Phaseline

Companies › Annexon

Annexon: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Ophthalmology, Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tanruprubart (ANX005)
C3 complement inhibitor
C3Phase 3Guillain-Barre SyndromeMay 2027
Vonaprument (ANX007)
Complement 3 (C3) inhibitor
C3Phase 3Geographic AtrophyJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07020819Tanruprubart (ANX005)Phase 3Guillain-Barre SyndromeNeurologyMay 2027
NCT06510816Vonaprument (ANX007)Phase 3Geographic AtrophyOphthalmologyJul 2027

From the company's SEC filings

Cash and short-term investments of $213m on 2026-09-30; operating cash outflow about $193m a year; runway about 13 months at that burn, to Nov 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

C3 (2)

Companies with the same targets

Apellis Pharmaceuticals Kodiak Sciences Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Shenyang Sunshine Pharmaceutical Swedish Orphan Biovitrum

Companies built like this

Oculis NervGen Pharma Immunic Alpha Cognition Immunovant Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.